Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Pfizer sees revenues double to $81bn thanks to COVID-19 vaccine

Pfizer sees revenues double to $81bn thanks to COVID-19 vaccine

The US drugs giant, which sold $37bn worth of the jab last year and expects sales of $32bn this year, said it had put "billions of dollars of capital on the line" in the early stages of the pandemic to develop the drug.

Drugs giant Pfizer has doubled annual sales and profits thanks to its COVID-19 vaccine.

The US firm said revenues rose from $41.7bn in 2020 to $81.3bn last year, largely thanks to the vaccine, known as Comirnaty - which accounted for $36.8bn of the total.

Profits climbed from $9.2bn to $22bn.

Pfizer's antiviral pill aims to reduce hospitalisation and deaths in high-risk patients


Pfizer said it expected sales of the vaccine - developed with Germany's BioNTech - to be worth $32bn this year, but that figure fell short of analysts' expectations for around $34bn.

It pencilled in a revenue figure of $22bn for COVID-19 oral antiviral treatment Paxlovid for 2022, which also fell a little short of Wall Street's target. Shares fell 3%.

Pfizer's vaccine is used in more than 160 countries.

It aims to make more than four billion doses in 2022, compared with last year's three billion.

Paxlovid has shown promise in cutting hospitalisation and deaths in high-risk patients and the company expects to produce at least 120 million courses of the pill this year.

Pfizer chief executive Albert Bourla said that in the early days of the COVID-19 pandemic, the company put "all of the resources and expertise we had at our disposal to help protect populations globally against this deadly virus as well as to offer treatments to help avoid the worst outcomes".

Albert Bourla said Pfizer's work had 'made a positive difference in the world'.


"We put billions of dollars of capital on the line in pursuit of those goals, not knowing whether those investments would ever pay off," Dr Bourla added.

He said that the successes of its COVID-19 treatments had "made a positive difference in the world".

Pfizer's results showed that it sold $7.8bn worth of its jab in the US, $9.4bn in western Europe and $8.1bn in other developed nations including Canada, Japan, South Korea, Australia and New Zealand.

Sales of Comirnaty to emerging markets - including the rest of Asia, Africa, the Middle East, Latin America and central and eastern Europe, totalled $11.4bn.

The amount of money being made by some drug companies from coronavirus jabs has proved controversial and campaigners have called for a waiver on vaccine patents, in order to allow cheap generic versions to be produced and distributed in poorer countries.

In December, World Health Organisation boss Tedros Adhanom Ghebreyesus warned that widespread COVID-19 vaccine booster programmes in developed countries were "likely to prolong the pandemic".

That was because, he said, they risked diverting supply to countries that had high levels of their populations already jabbed and away from those that need it most.

Anglo-Swedish drugs giant AstraZeneca, which reports full-year results later this week, has in contrast to rivals been selling its COVID-19 at cost.

But it was criticised when late last year it said it now planned to start making a "modest" profit from the drug.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
France Faces New Political Crisis, again, as Prime Minister Bayrou Pushed Out
Nayib Bukele Points Out Belgian Hypocrisy as Brussels Considers Sending Army into the Streets
France, at an Impasse, Heads Toward Another Government Collapse
The Country That Got Too Rich? Public Spending Dominates Norway Election
EU Proposes Phasing Out Russian Oil and Gas by End of 2027 to End Energy Dependence
More Than 150,000 Followers for a Fictional Character: The New Influencers Are AI Creations
EU Prepares for War
Trump Threatens Retaliatory Tariffs After EU Imposes €2.95 Billion Fine on Google
Tesla Board Proposes Unprecedented One-Trillion-Dollar Performance Package for Elon Musk
Gold Could Reach Nearly $5,000 if Fed Independence Is Undermined, Goldman Sachs Warns
Uruguay, Colombia and Paraguay Secure Places at 2026 World Cup
Trump Administration Advances Plans to Rebrand Pentagon as Department of War Instead of the Fake Term Department of Defense
Big Tech Executives Laud Trump at White House Dinner, Unveil Massive U.S. Investments
Tether Expands into Gold Sector with Profit-Driven Diversification
‘Looks Like a Wig’: Online Users Express Concern Over Kate Middleton
Florida’s Vaccine Revolution: DeSantis Declares War on Mandates
Trump’s New War – and the ‘Drug Tyrant’ Fearing Invasion: ‘1,200 Missiles Aimed at Us’
"The Situation Has Never Been This Bad": The Fall of PepsiCo
At the Parade in China: Laser Weapons, 'Eagle Strike,' and a Missile Capable of 'Striking Anywhere in the World'
The Fashion Designer Who Became an Italian Symbol: Giorgio Armani Has Died at 91
Putin Celebrates ‘Unprecedentedly High’ Ties with China as Gazprom Seals Power of Siberia-2 Deal
China Unveils New Weapons in Grand Military Parade as Xi Hosts Putin and Kim
Rapper Cardi B Cleared of Liability in Los Angeles Civil Assault Trial
Google Avoids Break-Up in U.S. Antitrust Case as Stocks Rise
Couple celebrates 80th wedding anniversary at assisted living facility in Lancaster
Information Warfare in the Age of AI: How Language Models Become Targets and Tools
The White House on LinkedIn Has Changed Their Profile Picture to Donald Trump
"Insulted the Prophet Muhammad": Woman Burned Alive by Angry Mob in Niger State, Nigeria
Trump Responds to Death Rumors – Announces 'Missile City'
Druzhba Pipeline Incident Sparks Geopolitical Tensions
Cost of Opposition Leader Péter Magyar's Economic Plan Revealed
Germany in Turmoil: Ukrainian Teenage Girl Pushed to Death by Illegal Iraqi Migrant
United Krack down on human rights: Graham Linehan Arrested at Heathrow Over Three X Posts, Hospitalised, Released on Bail with Posting Ban
Asian and Middle Eastern Investors Avoid US Markets
Ray Dalio Warns of US Shift to Autocracy
Eurozone Inflation Rises to 2.1% in August
Russia and China Sign New Gas Pipeline Deal
Von der Leyen's Plane Hit by Suspected Russian GPS Interference in an Incident Believed to Be Caused by Russia or by Pro-Peace or by Anti-Corruption European Activists
China's Robotics Industry Fuels Export Surge
Suntory Chairman Resigns After Police Probe
Gold Price Hits New All-Time Record
UK Fintechs Explore Buying US Banks
Greece Suspends 5% of Schools as Birth Rate Drops
Apollo to Launch $5 Billion Sports Investment Vehicle
Bolsonaro Trial Nears Close Amid US-Brazil Tension
European Banks Push for Lower Cross-Border Barriers
Poland's Offshore Wind Sector Attracts Investors
Budapest Central European Fashion Week Kicks Off
U.S. Celebrates Labor Day
Hungarian National Team Captain Scores Epic Goal
×